WAM
IRWD icon

Wakefield Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Wakefield Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-52,930
Closed -$603K – 167
2020
Q4 		$603K Buy
+52,930
New +$579K 0.25% 121

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Wakefield Asset Management's IRWD Position: Q1 2021 in Review

Wakefield Asset Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2021, closing a stake of 52,930 shares — an estimated $603K sold.

Wakefield Asset Management first reported a position in IRWD in Q4 2020 and held it in 1 quarter. The position peaked at $603K in Q4 2020. 209 funds tracked by Wall St. Rank hold IRWD as of Q1 2021.

  • Wakefield Asset Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Wakefield Asset Management sold 52,930 Ironwood Pharmaceuticals shares in Q1 2021, an estimated $603K.
  • Wakefield Asset Management first reported a position in Ironwood Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Wakefield Asset Management's Ironwood Pharmaceuticals position peaked at $603K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2021.

Based on Wakefield Asset Management's 13F filing for Q1 2021, filed 11 May 2021.